References
Acton EM, Tong GL, Mosher CW et al. (1984) Intensely potent morpholinyl anthracyclines. J Med Chem 27 638–645
Armand JP (1984) Phase II and phase III studies with equirubicin in breast cancer in France. In Bonadonna G (ed) Advances in anthracycline chemotherapy epirubicin. Masson, Milan, pp 75–82
Arcamone E (1980) The development of new antitumor anthracyclines. Med Chem 16: 1–41
Arcamone F, Cassinelli G, Orezzi P et al. (1964) Daunomycin II. The structure and stereochemistry of daunosamine. J Am Chem Soc 86: 5335–5336
Arcamone F, Penco S, Vigevani A et al (1975) Synthesis and antitumor properties of new glycosides of daunomycinone and adriamycinone. J Med Chem 18: 703–707
Arcamone F, Penco S, Vigevani A (1975) Adriamycin (NSC-123127) new chemical developments and analogs. Cancer Chemother Rep (3): 6: 123–129
Arcamone F, Penco S, Redaelli S et al. (1976) Synthesis and antitumor activity of 4′-deoxydaunorubicin and 4′-deoxyadriamycin. J Med Chem 19: 1424–1425
Arcamone F, Bernardi L, Giardino P et al. (1976) Synthesis and antitumor activity of 4-demethoxydaunorubicin, 4-demethoxy-7,9-diepidaunorubicin, and their β anomers. Cancer Treat Rep 60: 829–834
Berman E, Wittes RE, Leyland-Jones B et al. (1983) Phase I and clinical pharmacology studies of intravenous and oral administration of 4-demethoxydaunorubicin in patients with advanced cancer. Cancer Res 43: 6096–6101
Berman E, Casper ES, Howard J et al. (1984) Phase II trial of 4′-epi-doxorubicin in patients with advanced malignant melanoma. Cancer Treat Rep 68: 679–680
Bhuyan BK, McGovren JP, Crampton SL (1981) Intracellular uptake of 7-con-O-methylnogarol and adriamycin by cells in culture and its relationship to cell survival. Cancer Res 41: 882–887
Blum RH, Garnick MB, Israel M (1979) Initial clinical evaluation of N-trifluoroacetyladriamycin 14-valerate (AD-32), an adriamycin analog. Cancer Treat Rep 63: 919–923
Bonadonna G, Monfardini S, de Lena M et al. (1969) Clinical evaluation of adriamycin, a new antitumour antibiotic. Br Med J 3: 503–506
Bonadonna G, Brambilla, Rossi A, et al. (1984) Epirubicin in advanced breast cancer. The experience of the Milan Cancer Institute. In Bonadonna G (ed) Advances in anthracycline chemotherapy epirubicin. Masson, Milan, pp 63–70
Bonfante V, Bonadonna G, Villani F et al. (1979) Preliminary phase I study of 4′-epi-adriamycin. Cancer Treat Rep 63: 915–918
Bonfante V, Villani F, Bonadonna G (1982) Toxic and therapeutic activity of 4′-epi-doxorubicin. Tumori 68: 105–111
Bonfante V, Ferrari L, Villani F et al. (1983) Phase I study of 4-demethoxydaunorubicin. Invest New Drugs 1 161–168
Bonfante V, Rossi A, Brambilla C et al. (1985) Comparative activity and toxicity of adriamycin (ADM) and new anthracycline analogs in advanced breast cancer (abstract). Proc Am Assoc Cancer Res 26: 165
Broggini M, Colombo T, Martini A et al. (1980) Studies on the comparative distribution and biliary excretion of doxorubicin and 4′-epi-doxorubicin in mice and rats. Cancer Treat Rep 64: 897–904
Broggini M, Italia C, Colombo T et al. (1984) Activity and distribution of iv and oral 4-demethoxydaunorubicin in murine experimental tumors. Cancer Treat Rep 68 739–747
Brown TD, Donehower RC, Grochow LB et al. (1985) A phase I study of menogaril (MEN) in patients with advanced cancer (abstract). Proc Am Soc Clin Oncol 4: 32
Bull JM, Tormey DC, Li S-H et al. (1978) A randomized comparative trial of adriamycin versus methotrexate in combination drug therapy. Cancer 41: 1649–1657
Campora E, Nobile MT, Sertoli MR et al. (1984) Phase II study of 4′-epi-doxorubicin in advanced breast cancer. Cancer Treat Rep 68: 1285–1286
Carella AM, Santini G, Martinengo M et al. (1985) 4-demethoxydaunorubicin (idarubicin) in refractory or relapsed acute leukemias. A pilot study. Cancer 55: 1452–1454
Carella AM, Santini G, Giordano D et al. (1985) Idarubicin alone or in combination with citarabine and etoposide (3+3+5 protocol) in acute non-lymphoblastic leukaemia. Leukemia Res 9: 631
Casazza AM (1979) Experimental evaluation of anthracycline analogs. Cancer Treat Rep 63: 835–844
Casazza AM, Guiliani FC (1984) Preclinical properties of epirubicin. In Bonadonna G (ed) Advances in anthracycline chemotherapy epirubicin. Masson, Milan, pp 31–40
Casazza AM, Di Marco A, Bertazzoli C et al. (1978) Antitumor activity, toxicity, and pharmacological properties of 4′-epi-adriamycin. In Siegenthaler A, L▵hy R (eds) Current chemotherapy, vol 2. American Society of Microbiology, Washington, pp 1257–1260
Casazza AM, Di Marco A, Bonadonna G et al. (1980) Effects of modifications in position 4 of the chromophore or in position 4′ of the aminosugar, on the antitumor activity and toxicity of daunorubicin and doxorubicin. In Crooke ST, Reich SD (eds) Anthracyclines current status and new developments. Academic, New York, pp 403–430
Casazza AM, Pratesi G, Giuliani et al. (1980) Antileukemia activity of 4-demethoxydaunorubicin in mice. Tumori 66 549–564
Casazza AM, Savi G, Pratesi G et al. (1983) Antitumor activity in mice of 4′-deoxydoxorubicin in comparison with doxorubicin. Eur J Cancer Clin Oncol 19: 411–418
Casazza AM, Barbieri B, Fumagalli A et al. (1981) Biologic activity of 4-demethoxy-13-dihydrodaunorubicin (4-dm-13-OH-DNR) (abstract). Proc Am Assoc Cancer Res 24 251
Daghestani AN, Arlin ZA, Leyland-Jones B et al. (1985) Phase I and II clinical and pharmacological study of 4-demethoxydaunorubicin (idarubicin) in adult patients with acute leukemia. Cancer Res 45: 1408–1412
Dickinson AC, DeJordy JO, Boutin MG et al. (1984) Absence of generation of oxygen-containing free radicals with 4′-deoxydoxorubicin, a non-cardiotoxic anthracycline drug. Biochem Biophys Res Commun 125: 584–591
Di Marco A, Gaetani M, Dorigotti L et al. (1963) Studi sperimentali sull ‘attivita’ antineoplastica del nuovo antibiotico daunomicina. Tumori 49: 203–217
Di Marco A, Gaetani M, Scarpinato B (1969) Adriamycin (NSC-123,127) a new antibiotic with antitumor activity. Cancer Chemother Rep (1) 53: 33–37
Di Marco A, Casazza AM, Pratesi G (1977) Antitumor activity of 4-demethoxydaunorubicin administered orally. Cancer Treat Rep 62: 893–894
Di Marco A, Zunino F, Casazza AM (1978) Comparison of biochemical and biological methods in the evaluation of new anthracycline drugs. Antibiotics Chemother 23: 12–20
Dodion P, Davis TA, Rozencweig M et al. (1985) Human pharmacokinetics of esorubicin (4′-deoxydoxorubicin). Invest New Drugs 3: 361–368
Dodion P, Sessa C, Gerard N et al. (1985) Phase I trial of menogaril (M) with a single dose schedule (abstract). Proc Am Soc Clin Oncol 4: 26
Dorr FA, Von Hoff DD, Kuhn JG et al. (in press) Phase I clinical investigation of 7-con-O-methylnogaril, a new anthracycline antibiotic. Invest New Drugs
Dubost M, Ganter P, Maral R et al. (1964) Rubidomycin a new antibiotic with cytostatic properties. Cancer Chemother Rep 41: 35–36
Egorin MJ, Van Echo DA, Whitacre MY et al. (1986) Human pharmacokinetics, excretion, and metabolism of the anthracycline antibiotic menogaril (NSC 269148, 7-OMEN) and their correlation with clinical toxicities. Cancer Res 46: 1513–1520
Einzig A, Kelsen D, Cheng E et al. (1984) Phase II study of 4-demethoxydaunorubicin in patients with adenocarcinoma of the upper gastrointestinal tract. Cancer Treat Rep 68 1415–1416
Ferrari L, Rossi A, Brambilla C et al. (1984) Phase I study with 4′-deoxydoxorubicin. Invest New Drugs 2: 287–295
Formelli F, Pollini C, Casazza AM et al. (1981) Fluorescence assays and pharmacokinetic studies of 4′-deoxydoxorubicin and doxorubicin in organs of mice bearing solid tumors. Cancer Chemother Pharmacol 5: 139–144
Fossa SD, Wik B, Bae E, et al. (1982) Phase II study of 4′-epi-doxorubicin in metastatic renal cancer. Cancer Treat Rep 66: 1219–1221
Ganzina F (1983) 4′-epi-doxorubicin, a new analogue of doxorubicin a preliminary overview of preclinical and clinical data. Cancer Treat Rev 10: 1–22
Garewal HS, Robertone A, Salmon SE et al. (1984) Phase I trial of esorubicin (4′-deoxydoxorubicin). J Clin Oncol 2 1034–1039
Gause GF, Brazhnikova MG, Shorin VA (1974) A new antitumor antibiotic, carminomycin (NSC-180024). Cancer Chemother Rep (1) 58: 255–256
Ghione M (1975) Development of adriamycin (NSC-123127). Cancer Chemother Rep (3) 6: 83–89
Giuliani FC, Kaplan NO (1980) New doxorubicin analogs active against doxorubicin-resistant colon tumor xenografts in the nude mouse. Cancer Res 40: 4682–4687
Giuliani FC, Zirvi KA, Kaplan NO et al. (1981) Chemotherapy of human colorectal tumor xenografts in athymic mice with clinically active drugs 5-fluorouracil and 1-3-Bis-(2-chloroethyl)-1-nitrosourea (BCNU). Comparison with doxorubicin derivatives 4′-deoxydoxorubicin and 4′-O-methyldoxorubicin. Int J Cancer 27: 5–13
Goldin A, Venditti JM, Geran R (1985) The effectiveness of the anthracycline analog 4′-epidoxorubicin in the treatment of experimental tumors a review. Invest New Drugs 3 3–21
Hakes TB, Daghestani AN, Dougherty JB et al. (1985) Phase II study of 4-demethoxydaunorubicin in advanced ovarian carcinoma. Cancer Treat Rep 69: 559–560
Harper HD, Kemeny NE, Ahmed T et al. (1984) Phase II trial of 4-demethoxydaunorubicin in advanced colorectal carcinoma. Cancer Treat Rep 618: 689–690
Hayat M, Hurteloup P, Parmentier C et al. (1984) Phase I trial of idarubicin (4-demethoxydaunorubicin) in adult acute leukemia. Invest New Drugs 2: 375–379
Hochster HS, Green MD, Speyer J et al. (1985) 4′-epidoxorubicin (epirubicin) activity in hepatocellular carcinoma. J Clin Oncol 3: 1535–1540
Holdener EE, Hansen HH, Høst H et al. (1985) Epirubicin in colorectal cancer. A phase II study of the early clinical trials group (EORTC). Invest New Drugs 3: 63–66
Holdener EE, Cavalli F, Hansen HH et al. (1985) Phase II trial of esorubicin in advanced colorectal cancer (abstract). Proc Am Soc Clin Oncol 4: 93
Hortobagyi G, Yap HY, Aboud A et al. (1984) Doxorubicin (D) vs 4′-epidoxorubicin (4ED) for metastatic breast cancer (MBC) a prospective randomized study (abstract). Proc Am Soc Clin Oncol 3: 121
Hurteloup P, Cappelaere P, Armand JP et al. (1983) Phase II clinical evaluation of 4′-epi-doxorubicin. Cancer Treat Rep 67: 337–341
Jain KK, Casper ES, Geller NL et al. (1985) A prospective randomized comparison of epirubicin and doxorubicin in patients with advanced breast cancer. J Clin Oncol 3 818–826
Jensen RA, Acton EM, Peters JH (1984) Electrocardiographic and transmembrane potential effects of 5-iminodaunorubicin in the rat. Cancer Res 44: 4030–4039
Joss RA, Hansen HH, Hansen M et al. (1984) Phase II trial of epirubicin in advanced squamous, adeno- and large cell carcinoma of the lung. Eur J Cancer Clin Oncol 20 495–499
Joss RA, Obrecht J-P, Alberto P et al. (1984) Phase II trial of 4-demethoxydaunorubicin in patients with non-small cell lung cancer. Cancer Treat Rep 68: 563–564
Kaplan S, Sessa C, Willems Y et al. (1984) Phase I trial of 4-demethoxydaunorubicin (idarubicin) with single oral doses. Invest New Drugs 2: 281–286
Kaplan S, Sessa C, Joss R et al. (1985) Phase II trial of 4′-deoxydoxorubicin in advanced non-small cell lung cancer. Cancer Treat Rep 69: 1337–1338
Kris MG, Gralla RJ, Kelsen DP et al. (1985) Phase II trial of oral 4-demethoxydaunorubicin in patients with non-small cell lung cancer. Am J Clin Oncol (CCT) 8: 377–379
Lambertenghi-Deliliers G, Maiolo AT, Annaloro C et al. (1984) Complete remission in prolymphocytic leukemia with 4-demethoxydaunorubicin and arabinosyl cytosine. Cancer 54: 199–201
Leitner SP, Casper ES, Hakes TB et al. (1985) Phase II trial of 4′-deoxydoxorubicin in patients with advanced breast cancer. Cancer Treat Rep 69: 1319–1320
Lopez M, Perno C-F, Papaldo P et al. (1984) Phase II study of epirubicin in advanced malignant melanoma. Invest New Drugs 2: 315–317
Lopez M, Di Lauro L, Ganzina F et al. (1985) Epirubicin in non-Hodgkin's lymphomas. Am J Clin Oncol (CCT) 8 151–153
Macrez C, Marneffe-Lebrequier H, Ripault J et al. (1967) Accidents cardiaques observés au cours des traitements par la rubidomycine. Pathol-Biol 15: 949–953
Martoni A, Pacciarini MA, Pannuti F et al. (1985) Activity of 4-demethoxydaunorubicin by the oral route in advanced breast cancer. Eur J Cancer Clin Oncol 21: 803–806
Mathé G, Umezawa H, Tapiero H et al. (1985) Oriented phase II trial in advanced breast cancer of 4′-o-tetrahydropyranyl-adriamycin (THP-ADM), a non hair, non heart toxic anthracycline (abstract). Proc Am Soc Clin Oncol 4 71
McGovren JP (1980) Activity of the anthracycline agent, 7-con-O-methylnogarol (7-OMEN) administered orally to mice bearing P388 or L1210 leukemia. Cancer Treat Rep 64: 727–729
McGovren JP, Neil GL, Denlinger RH et al. (1979) Chronic cardiotoxicity studies in rabbits with 7-con-O-methylnogarol, a new anthracycline antitumor agent. Cancer Res 39 4849–4855
McGovren JP, Nelson KG, Lassus M et al. (1984) Menogaril a new anthracycline agent entering clinical trials. Invest New Drugs 2: 359–367
Meyers FJ, Lewis B, Mitchell E et al. (1985) Phase II trial of 4′-epi-doxorubicin in advanced colorectal carcinoma a Northern California Oncology Group study. Cancer Treat Rep 69: 143–144
Michaelson R, Kemeny N, Young C (1982) Phase II evaluation of 4′-epi-doxorubicin in patients with advanced colorectal carcinoma. Cancer Treat Rep 66: 1757–1758
Monti E, Piccinini F, Favalli L, et al. (1983) Role of the fast-exchanging calcium compartment in the early cardiotoxicity of anthracycline analogs. Biochem Pharmacol 32 3303–3306
Morin MJ, Sartorelli AC (1984) Inhibition of glycoprotein biosynthesis by the inducers of HL-60 cell differentiation, aclacinomycin A and marcellomycin. Cancer Res 44 2807–2812
Mouridsen HT, Somers R, Santoro A et al. (1984) Doxorubicin vs. epirubicin in advanced soft tissue sarcomas. An EORTC randomized phase II study. In Bonadonna G (ed) Advances in arthracycline chemotherapy epirubicin. Masson, Milan, pp 95–103
Nicaise C, Rozencweig M, DeMarneffe M et al. (1983) Clinical phase I trial with marcellomycin with a single-dose schedule. Eur J Cancer Clin Oncol 19: 449–454
Penco S, Casazza AM, Franchi G et al. (1983) Synthesis, antitumor activity, and cardiac toxicity of new 4-demethoxyanthracyclines. Cancer Treat Rep 67: 665–673
Pratesi G, Deschner EE (1984) The antitumoral activity of 4′-deoxydoxorubicin compared to doxorubicin and 5-fluorouracil in methylazoxymethanol acetate-induced colon tumors in CF1 mice. Cancer 54: 18–24
Ringenberg S, Propert K, Perry M et al. (1986) Deoxydoxorubicin (DxDx) in extensive non-small cell lung cancer (NSCLC) (abstract). Proc Am Soc Clin Oncol 5: 174
Ripault J, Weil M, Jacquillat C (1967) Etude nécropsique de quatre malades traités par la rubidomycine. Pathol-Biol 15: 955–957
Robert J, Vrignaud P, Nguyen-Ngoc T et al. (1985) Comparative pharmacokinetics and metabolism of doxorubicin and epirubicin in patients with metastatic breast cancer. Cancer Treat Rep 69: 633–640
Rozencweig M, Crespeigne N, Kenis Y (1983) Phase I trial with 4′-deoxydoxorubicin (esorubicin). Invest New Drugs 1: 309–313
Rozencweig M, ten Bokkel Huinink W, Cavalli F et al. (1984) Randomized phase II trial of carminomycin versus 4′-epidoxorubicin in advanced breast cancer. J Clin Oncol 2: 275–281
Scarffe JH, Kenny JB, Johnson RJ et al. (1985) Phase II trial of epirubicin in gastric cancer. Cancer Treat Rep 69 1275–1277
Schauer PK, Wittes RE, Gralla RJ (1981) A phase I trial of 4′-epi-Adriamycin. Cancer Clin Trials 4: 433–437
Scher HI, Yagoda A, Ahmed T et al. (1985) Phase-II trial of 4-demethoxydaunorubicin (DMDR) for advanced hypernephroma. Cancer Chemother Pharmacol 14: 79–80
Sessa C, Bosia L, Kaplan S et al. (1984) Phase I study of 4′-deoxydoxorubicin given weekly. Invest New Drugs 2 369–374
Sigman LM, Van Echo DA, Egorin MJ et al. (1985) Menogaril (7-OMEN, NSC 269148) phase I study (abstract). Proc Am Assoc Cancer Res 26: 170
Stanton GF, Raymond V, Wittes RE et al. (1985) Phase I and clinical pharmacological evaluation of 4′-deoxydoxorubicin in patients with advanced cancer. Cancer Res 45 1862–1868
Stanton G, Casper ES, Friedman B (1985) Phase II trial of 4-demethoxydaunorubicin in patients with advanced malignant melanoma. Cancer Treat Rep 69: 915–916
Supino R, Necco A, Dasdia T et al. (1977) Relationship between effects on nucleic acid synthesis in cell cultures and cytotoxicity of 4-demethoxy derivatives of daunorubicin and adriamycin. Cancer Res 37: 4523–4528
Tan C, Etcubanas E, Wollner N et al. (1973) Adriamycin —an antitumor antibiotic in the treatment of neoplastic diseases. Cancer 32: 9–17
Torti FM, Porzig KJ, Gandara DR et al. (1984) Phase II trial of 4′-epi-doxorubicin in metastatic melanoma. Cancer Treat Rep 68: 1509–1510
Weenen H, Lankelma J, Penders PGM et al. (1983) Pharmacokinetics of 4′epi-doxorubicin in man. Invest New Drugs 1: 59–64
Weenen H, Van Maanen JMS, De Planque MM et al. (1984) Metabolism of 4′-modified analogs of doxorubicin. Unique glucuronidation pathway for 4′-epidoxorubicin. Eur J Cancer Clin Oncol 20: 919–926
Weiss RB, Bruno S (1981) Daunorubicin treatment of adult solid tumors. Cancer Treat Rep 65 [Suppl 4]: 25–28
Wils JA (1984) Phase II trial of 4′-epi-doxorubicin in metastatic colorectal carcinoma. Invest New Drugs 2: 397–399
Wils J, Bleiberg H, Blijham G et al. (1985) Phase II study of epirubicin in advanced adenocarcinoma of the pancreas. Eur J Cancer Clin Oncol 21: 191–194
Wiley PF, Johnson JL, Houser DJ (1977) Nogalamycin analogs having improved antitumor activity. J Antibiot 30 628–629
Author information
Authors and Affiliations
Additional information
The opinions expressed in this article are solely those of the authors and are not necessarily those of any government agency
Rights and permissions
About this article
Cite this article
Weiss, R.B., Sarosy, G., Clagett-Carr, K. et al. Anthracycline analogs The past, present, and future. Cancer Chemother. Pharmacol. 18, 185–197 (1986). https://doi.org/10.1007/BF00273384
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00273384